Published in N Engl J Med on August 22, 2013
The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness | NCT02423512
Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy | NCT03577782
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (2015) 2.74
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol (2015) 2.64
Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56
Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis. J Leukoc Biol (2015) 1.46
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol (2016) 1.39
Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med (2014) 1.32
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nat Rev Drug Discov (2015) 1.14
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut (2014) 1.11
Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. Am J Gastroenterol (2015) 1.07
Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov (2016) 1.06
Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol (2014) 1.03
Treatment of IBD: where we are and where we are going. Am J Gastroenterol (2014) 1.02
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol (2014) 0.99
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis (2015) 0.99
Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2015) 0.98
Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors. Front Immunol (2015) 0.95
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol (2015) 0.94
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol (2015) 0.93
Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol (2015) 0.93
Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med (2013) 0.92
Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol (2015) 0.91
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol (2016) 0.90
The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol (2015) 0.90
New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) (2014) 0.89
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm (2015) 0.89
Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J (2015) 0.88
Oral pathology in inflammatory bowel disease. World J Gastroenterol (2016) 0.86
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther (2015) 0.86
Leukocyte Trafficking to the Small Intestine and Colon. Gastroenterology (2015) 0.85
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet (2017) 0.85
Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis (2014) 0.84
Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis (2015) 0.84
Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol (2015) 0.84
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J (2014) 0.83
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis (2015) 0.83
Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis (2016) 0.83
CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment? J Immunol Res (2015) 0.83
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol (2016) 0.82
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut (2015) 0.81
Therapeutic approaches for celiac disease. Best Pract Res Clin Gastroenterol (2015) 0.81
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. Biomed Res Int (2014) 0.81
Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep (2015) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2014) 0.81
Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. Curr Opin Gastroenterol (2015) 0.80
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol (2015) 0.80
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. Therap Adv Gastroenterol (2016) 0.80
Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology (2016) 0.80
Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. Expert Opin Investig Drugs (2016) 0.79
Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore) (2015) 0.79
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79
Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol (2014) 0.79
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight (2017) 0.78
T cell-associated α4β7 but not α4β1 integrin is required for the induction and perpetuation of chronic colitis. Mucosal Immunol (2014) 0.78
Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci (2015) 0.78
Current therapy of pediatric Crohn's disease. World J Gastrointest Pathophysiol (2015) 0.78
Current stage in inflammatory bowel disease: What is next? World J Gastroenterol (2015) 0.78
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res (2014) 0.78
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther (2017) 0.77
Interaction of obesity and inflammatory bowel disease. World J Gastroenterol (2016) 0.77
Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol (2016) 0.77
Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). Int J Oncol (2015) 0.77
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol (2015) 0.77
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs (2014) 0.77
New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol (2015) 0.77
The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol (2016) 0.76
Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chronic Dis (2016) 0.76
Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol (2016) 0.76
Species-specific differences in the expression and regulation of α4β7 integrin in various nonhuman primates. J Immunol (2015) 0.76
What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med (2014) 0.76
Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol (2016) 0.76
Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther (2014) 0.76
Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol (2017) 0.75
The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol (2017) 0.75
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. Drug Des Devel Ther (2014) 0.75
Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol (2014) 0.75
Management of complex perianal Crohn's disease. Ann Gastroenterol (2016) 0.75
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw (2017) 0.75
Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis. World J Gastroenterol (2015) 0.75
Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. Br Dent J (2017) 0.75
Informatics-Based Discovery of Disease-Associated Immune Profiles. PLoS One (2016) 0.75
Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol (2017) 0.75
Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab. JAAD Case Rep (2017) 0.75
Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol (2016) 0.75
Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol (2015) 0.75
Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Arch Med Sci (2016) 0.75
Targeting αv Integrins in Pancreatic Fibrosis: Progress in Resolving the Scar. Cell Mol Gastroenterol Hepatol (2016) 0.75
Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol (2017) 0.75
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol (2017) 0.75
The Role of Biosimilars in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2016) 0.75
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol (2017) 0.75
Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 4.79
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Consequences of motor copy number on the intracellular transport of kinesin-1-driven lipid droplets. Cell (2008) 4.11
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension (2009) 3.48
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Asymmetric mating interactions drive widespread invasion and displacement in a whitefly. Science (2007) 3.17
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology (2003) 3.05
Postoperative impairment of cognitive function in rats: a possible role for cytokine-mediated inflammation in the hippocampus. Anesthesiology (2007) 3.02
Epidemiology of schistosomiasis in the People's Republic of China, 2004. Emerg Infect Dis (2007) 3.00
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol (2008) 2.88
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88